Register of
Medicinal Products

Product class: Medicinal product with marketing authorization
Medicinal product class: Human medicine
Name of medicinal product: BLASTOMAT 140 MG
Active substances:
Temozolomide
Estonian, English, Latin
ATC code: L01AX03
Dosage form: capsule, hard
Strength: 140mg
Legal status for supply*: Subject to medicinal prescription
Summary of product characteristics (SPC):  (last updated April 29, 2021)
Package information leaflet (PIL): EST  (last updated April 29, 2021)
Labelling:  (last updated September 12, 2018)
Indication: is indicated for the treatment of: - Adult patients with newly-diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment. - Children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.
Safety features: Yes
Marketing authorization holder: Zentiva k.s. 
Marketing authorization number: 799512 
Marketing authorization issued on: October 29, 2012 
Marketing authorization expires on: Unlimited 
Marketing authorization procedure type: Decentralised 
Assessment report:  (last updated December 3, 2013) 
Package code Name of medicinal product Dosage form Package Legal status Reimbursements Reference price Last imported PƤritolumaa Additional information
1534698  BLASTOMAT 140 MG  capsule, hard  140mg 5TK  Prescription  50% 100%  130,48  08.04.2024     
1534700  BLASTOMAT 140 MG  capsule, hard  140mg 20TK  Prescription           
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription

You can download Acrobat Reader fromhere